EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #04431_C
用于人细胞的含琼脂-LCM和EPO的甲基纤维素培养基
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
MethoCult™ H4431 是一种基于甲基纤维素的培养基，用于在人骨髓、动员外周血、外周血和脐带血样本的集落形成单位（CFU）检测中培养和计数造血祖细胞。MethoCult™ H4431 支持红系祖细胞（BFU-E和CFU-E）、粒细胞-巨噬细胞祖细胞（CFU-GM、CFU-G和CFU-M）以及多能粒细胞、红系、巨噬细胞、巨核细胞祖细胞（CFU-GEMM）的培养。该配方含有琼脂-白细胞条件培养基（Agar-LCM）作为集落刺激因子的来源，并添加重组人促红细胞生成素（EPO）。MethoCult™ H4431 适用于作为MethoCult™
H4531（产品号 #04531）检测“EPO非依赖性”红系祖细胞的对照培养基。
点击此处了解有关进行CFU检测的常见问题（FAQ），以及其在细胞治疗研究中的应用。
包含
• 含甲基纤维素的Iscove's MDM
• 胎牛血清
• 牛血清白蛋白
• 2-巯基乙醇
• 琼脂-LCM
• 重组人促红细胞生成素 (EPO)
• 添加物
分类
半固体培养基，专用培养基
细胞类型
造血干/祖细胞
种属
人
应用
细胞培养，克隆筛选，功能学筛选
品牌
MethoCult
研究领域
药物发现和毒性检测，干细胞生物学
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (6)
常见问题
文献 (10)
Retroviral vector-mediated gene transfer into umbilical cord blood CD34brCD38-CD33- cells.
Experimental hematology 1999 AUG
Abstract
In this report,we sought to optimize gene transfer into primitive human umbilical cord blood (UCB) cells. Initially,we found that fresh UCB isolated with the CD34brCD38 CD33 phenotype were highly enriched for hematopoietic progenitors detected in extended long-term cultures (8-week LTCs). In addition,following ex vivo gene transfer,this population possessed virtually all the 8-week LTC activity of the cultured cells. A multiparameter FACS assay was developed to efficiently screen the effects of alternative retroviral vector gene transfer procedures on the transduction efficiency and maintenance of CD34brCD38 CD33 cells. Proliferation of the CD34brCD38 CD33 cells was found to be a prerequisite for efficient transduction. However,in all conditions tested,proliferation of the CD34brCD38 CD33 cells was associated with a progressive loss of primitive cell properties including a reduction in CD34 expression,an increase in CD38/CD33 expression,and a decline in the ability to sustain 8-week LTCs. These observations indicate that it will be necessary to define conditions that more effectively support the self-renewal capacity of CD34brCD38 CD33 cells to optimize retroviral vector gene transfer in these cells. Evaluating these conditions and reagents will be facilitated by the multiparameter FACS assay described in this report.
Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
Experimental hematology 1999 AUG
Abstract
Bispecific antibodies directed against tumor-associated target antigens and to surface receptors mediating T-cell activation,such as the TCR/CD3 complex and the costimulatory receptor CD28,are capable of mediating T-cell activation resulting in tumor cell killing. In this study,we used the B-cell-associated antigens CD19 and CD20 as target structures on human leukemic cells. We found that a combination of bispecific antibody fragments (bsFab2) with target x CD3 and target x CD28 specificity induces vigorous autologous T-cell activation and killing of malignant cells in peripheral blood and bone marrow cultures from patients with chronic lymphocytic leukemia and follicular lymphoma. The bsFab2 targeting CD20 were considerably more effective than those binding to CD19. The colony-forming capacity of treated bone marrow was impaired due to large amounts of tumor necrosis factor alpha produced during bsFab2-induced T-cell activation. Neutralizing tumor necrosis factor alpha antibodies were found to reverse this negative effect without affecting T-cell activation and tumor cell killing. CD20 x CD28 bsFab2,when used alone rather than in combination,markedly improved the recognition of leukemic cells by allogeneic T cells. Therefore,these reagents may be capable of enhancing the immunogenicity of leukemic cells in general and,in particular,of increasing the antileukemic activity of allogeneic donor buffy coat cells in relapsed bone marrow transplanted patients.
Comparison of in vitro drug-sensitivity of human granulocyte-macrophage progenitors from two different origins: umbilical cord blood and bone marrow.
Experimental hematology 1999 NOV
Abstract
Predictive in vitro hematotoxicity assays using human cells will provide estimation of tolerable level and aid considerably the development of agents with greater therapeutic activity and less toxicity. Human hematopoietic cells can be derived from three sources: human bone marrow by sternal or femoral aspiration,mobilized peripheral blood,or umbilical cord blood samples collected from placentas after deliveries. Because of the difficulties to have a continuous supply of bone marrow cells from normal human donors and the related ethical problems,we performed a study to compare the sensitivity of human bone marrow cells (h-BMC) and human cord blood cells (h-CBC) to chemicals in order to confirm if h-CBC can readily replace bone marrow cells in checking the sensitivity of GM-CFU progenitors to drugs as preliminarily reported in literature. Our results showed that the prediction of IC50 values in human model is quite similar by using h-BMC or h-CBC. On the contrary,the type of medium influenced in a significant way the ICs determination of some drugs.
更多信息
| 物种 | 人 |
|---|---|
| Contains | • Methylcellulose in Iscove's MDM • Fetal bovine serum • Bovine serum albumin • 2-Mercaptoethanol • Agar-LCM • Recombinant human erythropoietin (EPO) • Supplements |
相关产品
-
MethoCult™ H4034 Optimum含重组细胞因子的甲基纤维素培养基，用于人细胞
-
MethoCult™ H4434 Classic用于人细胞的含重组细胞因子的甲基纤维素培养基
-
MethoCult™ H4435 Enriched用于人细胞的含重组细胞因子的甲基纤维素培养基
-
MethoCult™ H4531用于人细胞的含有琼脂-LCM（不含促红细胞生成素 EPO）的甲基纤维素培养基
沪公网安备31010102008431号
在线联系